Vaccine solutions rarely reach the public until after an outbreak abates; an Ebola vaccine was approved 5 years after peak outbreak and SARS, MERS, and Zika vaccines are still in clinical development. Despite massive leaps forward in rapid science, other regulatory bottlenecks are hamstringing the global effort for pandemic vaccines.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293492 | PMC |
| http://dx.doi.org/10.1016/j.tibtech.2020.06.004 | DOI Listing |
Publication Analysis
Top Keywords
regulatory bottlenecks
8
working hard
4
hard working?
4
working? regulatory
4
bottlenecks developing
4
developing covid-19
4
covid-19 vaccine
4
vaccine vaccine
4
vaccine solutions
4
solutions rarely
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!